Human medicinal products
PIL Readability Testing and Bridging
Demonstrating that patients can easily find and correctly understand the information in the patient information leaflet (PIL) is a mandatory part of marketing authorisation applications. We design, conduct and report readability tests and bridging reports in line with TİTCK guidelines, the European Commission readability guideline and CMDh documents.
Scope of service
Our scope of services
Readability (User) Testing
- Pre-test readability assessment of the PIL and recommendations for improvement
- Preparation of a product-specific question set and test protocol
- Recruitment of participants matching the target user profile
- Pilot test followed by test rounds
- Assessment of the acceptance criterion for each question: at least 16 of 20 participants must find and correctly understand the information
- PIL revisions between test rounds where needed
- Management of participant data in line with the Turkish Personal Data Protection Law (KVKK)
- Preparation of the readability test report in a format suitable for the marketing authorisation dossier
Bridging
- Demonstrating compliance on the basis of a previously tested PIL, without a new test
- Comparative analysis of content and layout similarity between the parent PIL and the daughter PIL
- Assessment of bridging suitability for new strengths, pharmaceutical forms, line extensions and similar cases
- Preparation of the bridging report in line with CMDh recommendations
- Identification of cases where bridging is not sufficient and recommendation of focused testing
Our process: Preliminary assessment → Protocol and question set → Testing → Reporting → Support in responding to authority questions
Frequently asked questions
Common questions
Answers are based on TİTCK’s Guideline on Packaging Information and Patient Leaflets for Human Medicinal Products (İRD-KLVZ-07, revision 18, 11.08.2026; Part 2: Readability), the Medicines Licensing Department’s Frequently Asked Questions document (16.02.2024), TİTCK’s Patient Leaflet FAQ and the CMDh bridging recommendations (CMDh/100/2007 Rev. 3, December 2017), and are for general information only. Current legislation and Agency announcements prevail.
Which applications require a readability test?
For all marketing authorisation applications, including hospital products, a commitment and protocol for completing the readability test must be submitted; only products that have an SmPC but no PIL are exempt. According to TİTCK, as readability tests have not been performed for products already on the market, generics also require a test, and the test must be performed even if the product will only be administered by a healthcare professional. The test applies to the PIL; no readability test is required for the packaging.
At which stage of the marketing authorisation process is the test submitted?
The readability test is submitted in Module 1.3.4. If the test has not been completed at the time of application, the CTD pre-assessment can be completed by placing in Module 1.3.4 a test protocol in line with the guideline and a commitment that the test will be completed during the licensing process. However, the marketing authorisation process cannot be completed until the test has been completed and submitted.
How is the test conducted, and what is the success criterion?
The Packaging Guideline calls for a diagnostic test: the PIL is given to the participant as a single document, and up to about 15 questions check whether critical information, such as what the medicine is for, how to use it and possible side effects, can be found and understood. Participants are drawn from at-risk groups (e.g. elderly people), and close-knit groups such as colleagues are avoided. Interviews are one-to-one and take 30–45 minutes per person; questions are asked in random order and participants answer orally in their own words. After the first 10 participants, the results are reviewed, the PIL is revised if needed and a further 10 people are tested. The success criterion is that at least 16 of 20 participants answer each question correctly; the same 16 people do not have to answer every question. As in the European Commission’s readability guideline, we pilot the question set before the main rounds.
What is bridging, and when is it accepted?
Bridging demonstrates the readability of a “daughter” PIL by reference to a previously and successfully tested “parent” PIL, without a new full test. Under the CMDh bridging recommendations, the two leaflets must be shown to be similar in both content (especially key safety messages) and layout and design (font and text size, headings, use of colour, writing style, layout of critical safety sections, pictograms); separate parent PILs may be used for content and for layout (double bridging). Typical examples are different strengths or routes of administration of the same active substance (line extensions), products in the same therapeutic class with similar key safety messages, and combination products; bridging is generally not accepted within groups whose members differ clinically, such as anti-arrhythmics and anti-epileptics. TİTCK accepts bridging where a publicly available readability test of the reference product abroad exists; the bridged product does not need to be authorised in Türkiye.
When is a focus test needed?
If the daughter PIL differs from the parent PIL in one or two points (e.g. a new route of administration or device), a test focusing only on those points is submitted together with the bridging report. TİTCK may also request a focus test when it considers that certain sections need re-assessment, or depending on the variation submitted.
What does a bridging report contain?
Under CMDh guidance, the bridging proposal is prepared using the CMDh QRD form (CMDh/365/2017) and submitted in Module 1.3.4. The report critically discusses how the key messages for safe use in the daughter PIL are covered by the parent PIL’s test, compares the design and layout of the two leaflets, and discusses the complexity of the messages and the language used. The parent PIL’s test data are not included; the parent PIL must already have been submitted and approved in another application.
Must the test be repeated when the PIL is updated?
Not every SmPC/PIL update requires a new test. Under CTD Module 1.3.4, post-authorisation applications in which the PIL has changed significantly must include readability information or a justification for not performing a test. If TİTCK decides, while assessing an update, that a readability test is needed, it notifies the applicant; depending on the scope of the change, a focus test may be requested. We assess the impact of an update using bridging principles and justify before submission whether a test is needed.
Can a test or bridging report performed abroad be used?
Yes. A readability test or bridging report performed abroad can be submitted with its Turkish translation; providing information on the bridged reference product is helpful. As it is a Module 1 document, the translation must be made by a sworn translator. The entire test and results report must be translated into Turkish.
How is participant information presented, and who may conduct the test?
Participants’ age, gender and education are important for evaluating the test and are reported in line with the Turkish Personal Data Protection Law (KVKK), in a way that does not identify individuals. The test does not have to be outsourced; what matters is that it meets the standards in the guideline, and the applicant is responsible for all Agency requests relating to the test.
Is readability only about testing? What design rules apply to the PIL and packaging?
No, the Packaging Guideline also sets design rules. The main ones are:
- PIL text in non-condensed type of at least 8 points (Times New Roman as reference); packaging text at least 7 points
- Line spacing at least 1.5 times the space between words on a line; no justified text and no extensive use of capitals
- Dark text on a light background; text and background never in similar colours
- Product name and strength in uncontracted Braille on the outer packaging; Marburg Medium recommended
- Large print, Braille or an audio PIL via multimedia QR code for blind and partially sighted users
In our pre-test review, we also check the PIL against these rules.
